MX369691B - Inhibidores de glutaminasa y métodos de empleo. - Google Patents

Inhibidores de glutaminasa y métodos de empleo.

Info

Publication number
MX369691B
MX369691B MX2015006478A MX2015006478A MX369691B MX 369691 B MX369691 B MX 369691B MX 2015006478 A MX2015006478 A MX 2015006478A MX 2015006478 A MX2015006478 A MX 2015006478A MX 369691 B MX369691 B MX 369691B
Authority
MX
Mexico
Prior art keywords
glutamase
inhibitors
compounds
inhibit glutaminase
cancer
Prior art date
Application number
MX2015006478A
Other languages
English (en)
Other versions
MX2015006478A (es
Inventor
M Lemieux Rene
G Salituro Francesco
Travins Jeremy
Yan Shunqi
Popovici-Muller Janeta
O Saunders Jeffrey
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2015006478A publication Critical patent/MX2015006478A/es
Publication of MX369691B publication Critical patent/MX369691B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)

Abstract

En la presente se describen compuestos y composiciones que comprenden compuestos que inhiben la glutaminasa. También se describen en la presente métodos de empleo de los compuestos que inhiben la glutaminasa en el tratamiento del cáncer.
MX2015006478A 2012-11-21 2013-11-21 Inhibidores de glutaminasa y métodos de empleo. MX369691B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261729321P 2012-11-21 2012-11-21
PCT/US2013/071212 WO2014081925A1 (en) 2012-11-21 2013-11-21 Glutamase inhibitors and method of use

Publications (2)

Publication Number Publication Date
MX2015006478A MX2015006478A (es) 2015-12-03
MX369691B true MX369691B (es) 2019-11-19

Family

ID=49780330

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006478A MX369691B (es) 2012-11-21 2013-11-21 Inhibidores de glutaminasa y métodos de empleo.

Country Status (15)

Country Link
US (3) US9303002B2 (es)
EP (1) EP2922832B1 (es)
JP (1) JP6333280B2 (es)
KR (1) KR20150085078A (es)
CN (1) CN105263915B (es)
AU (2) AU2013347933C1 (es)
BR (1) BR112015011756A2 (es)
CA (1) CA2892089A1 (es)
EA (1) EA029531B1 (es)
ES (1) ES2761951T3 (es)
HK (1) HK1213889A1 (es)
IL (1) IL238959A (es)
MX (1) MX369691B (es)
SG (1) SG11201504022RA (es)
WO (1) WO2014081925A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6026424B2 (ja) 2010-11-01 2016-11-16 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 治療薬送達のための生物浸食性ケイ素ベースのデバイス
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
PT2920168T (pt) 2012-11-16 2021-10-18 Calithera Biosciences Inc Inibidores heterocíclicos de glutaminase
CA2892089A1 (en) * 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
CA2934702A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Inhibitors of glutaminase
KR20160127149A (ko) 2014-03-21 2016-11-02 아지오스 파마슈티컬스 아이엔씨. 화합물 및 이의 사용 방법
WO2015166373A1 (en) 2014-04-30 2015-11-05 Pfizer Inc. Cycloalkyl-linked diheterocycle derivatives
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
EA036001B1 (ru) * 2014-06-13 2020-09-11 Калитера Байосайенсиз, Инк. Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких
CN107074805B (zh) 2014-07-03 2021-02-26 德州大学系统董事会 用于治疗疾病的gls1抑制剂
WO2016007647A1 (en) 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
EP3189070A4 (en) 2014-08-04 2018-06-27 Drexel University Novel compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
EP3277276B1 (en) * 2015-03-30 2020-11-04 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
SG11201708153XA (en) 2015-04-06 2017-11-29 Calithera Biosciences Inc Treatment of lung cancer with inhibitors of glutaminase
EP3316887B1 (en) 2015-06-30 2020-04-08 Board of Regents, The University of Texas System Gls1 inhibitors for treating disease
JP6971239B2 (ja) 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
BR112018012660B1 (pt) 2015-12-22 2023-12-19 Board Of Regents, The University Of Texas System Sal, solvato, ou polimorfo de um composto; polimorfo de composto sólido; composição; e uso de um sal, solvato ou polimorfo
US10278968B2 (en) 2016-08-25 2019-05-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN109982703A (zh) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
CN107137401A (zh) * 2017-03-28 2017-09-08 刘纪君 一种治疗产后抑郁症的药物组合物
US10722487B2 (en) 2017-10-18 2020-07-28 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN114805346A (zh) * 2021-07-08 2022-07-29 成都硕德药业有限公司 杂环类衍生物、其制备方法及用途
WO2025080100A1 (ko) * 2023-10-11 2025-04-17 한국화학연구원 신규한 디-아미드 화합물, 이의 제조방법, 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) * 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
CA2155759A1 (en) 1993-03-29 1994-10-13 Bernd Janssen 1-amino-3-phenoxy propane derivatives as modulators of multi-drug resistance
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
CA2332325A1 (en) 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
AU3316600A (en) 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
WO2001062206A2 (en) 2000-02-22 2001-08-30 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
DK1388734T3 (da) 2002-08-01 2004-05-03 Mtm Lab Ag Metode til opløsningsbaseret diagnose
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
ATE477495T1 (de) 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US8716472B2 (en) 2006-10-16 2014-05-06 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
WO2009067429A1 (en) 2007-11-19 2009-05-28 Genentech, Inc. Compositions and methods for inhibiting tumor progression
US7951549B2 (en) 2008-03-07 2011-05-31 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP3021120A1 (en) 2009-02-20 2016-05-18 Michael P. Lisanti Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample
WO2010111504A2 (en) 2009-03-25 2010-09-30 Cornell University Inhibition of glutaminase c
WO2010120966A1 (en) 2009-04-17 2010-10-21 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20130109643A1 (en) * 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
AU2011270968C1 (en) 2010-06-23 2017-01-19 University Of Louisville Research Foundation, Inc. Methods for detecting cancer
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013043125A1 (en) * 2011-09-20 2013-03-28 Temasek Life Sciences Laboratory Limited Enterovirus 71 specific antibodies and uses thereof
HUE047642T2 (hu) * 2011-11-21 2020-05-28 Calithera Biosciences Inc A glutamináz heterociklusos gátlói
KR20140138956A (ko) 2012-03-15 2014-12-04 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 Ｅ-카드헤린의 세포외 도메인의 저해제를 포함하는 병용 치료법
CA2892089A1 (en) 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014138391A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
CA2934702A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Inhibitors of glutaminase
KR20160127149A (ko) 2014-03-21 2016-11-02 아지오스 파마슈티컬스 아이엔씨. 화합물 및 이의 사용 방법

Also Published As

Publication number Publication date
AU2013347933B2 (en) 2018-03-29
US20150299152A1 (en) 2015-10-22
BR112015011756A2 (pt) 2017-07-11
CN105263915A (zh) 2016-01-20
HK1213889A1 (zh) 2016-07-15
KR20150085078A (ko) 2015-07-22
AU2013347933A2 (en) 2015-07-09
EA201590997A1 (ru) 2015-11-30
EP2922832A1 (en) 2015-09-30
US10011574B2 (en) 2018-07-03
JP2016500107A (ja) 2016-01-07
US9303002B2 (en) 2016-04-05
CN105263915B (zh) 2019-04-12
SG11201504022RA (en) 2015-06-29
IL238959A (en) 2017-12-31
AU2018204692A1 (en) 2018-07-19
MX2015006478A (es) 2015-12-03
EP2922832B1 (en) 2019-10-09
AU2013347933C1 (en) 2018-10-04
CA2892089A1 (en) 2014-05-30
IL238959A0 (en) 2015-07-30
ES2761951T3 (es) 2020-05-21
JP6333280B2 (ja) 2018-05-30
US20180370930A1 (en) 2018-12-27
US10414740B2 (en) 2019-09-17
US20140142146A1 (en) 2014-05-22
AU2013347933A1 (en) 2015-06-11
WO2014081925A1 (en) 2014-05-30
EA029531B1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
ZA202208792B (en) Methods of treating and preventing graft versus host disease
IL273090B (en) Methods and preparations for the treatment of cancer
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
EA201590987A1 (ru) Соединения и способы их применения
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
EP3004877A4 (en) Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
EP3169363A4 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
IL239453B (en) Preparations and methods for treating cancer using bacteria
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
PH12015500615A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
PH12014500925A1 (en) Therapeutic combinations and methods of treating melanoma
PH12016501838A1 (en) Compounds and their methods of use
MX2015013021A (es) 5-bromo-indirrubinas.
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MY182434A (en) Certain chemical entities, compositions, and methods

Legal Events

Date Code Title Description
FG Grant or registration